<DOC>
	<DOC>NCT00333840</DOC>
	<brief_summary>The purpose of this study is to evaluate and compare the side effects and anti-leukemic benefits of imatinib with those of interferon and Ara-C for patients who have chronic myeloid leukemia (CML) in the chronic phase. Patients in this study will be randomized (1:1) to receive either interferon plus Ara-C or imatinib as initial treatment.</brief_summary>
	<brief_title>Safety and Efficacy of Imatinib Versus Interferon-Î± Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
	<mesh_term>Philadelphia Chromosome</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Inclusion criteria: Must have signed consent for Amendment 5 Must have completed visit 62 of the core IRIS trial or be in followup Must be on STI571 treatment If on IFN treatment, must be willing to cross over to STI571 treatment Exclusion criteria: Patients who have discontinued from the study and are in followup Patients who are on IFN treatment and do not want to cross over to STI571 treatment Patients who have not consented to amendment 5 Patients who did not complete the amendment 5 protocol Additional protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>CML</keyword>
	<keyword>STI571</keyword>
	<keyword>imatinib</keyword>
	<keyword>interferon</keyword>
	<keyword>interferon alpha</keyword>
	<keyword>cytosine arabinoside</keyword>
	<keyword>chronic myeloid leukemia</keyword>
	<keyword>Philadelphia chromosome positive</keyword>
</DOC>